FDA approves first radioligand generic, setting up rivalry with Novartis
For the first time, Novartis’ leadership in the radioligand field will be tested by a generic rival. Curium announced on Monday that the FDA has approved its “radioligand equivalent” to Novartis’ Lutathera for the treatment ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.